These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 20539080)

  • 1. Soaring antiretroviral prices, TRIPS and TRIPS flexibilities: a burning issue for antiretroviral treatment scale-up in developing countries.
    Orsi F; d'almeida C
    Curr Opin HIV AIDS; 2010 May; 5(3):237-41. PubMed ID: 20539080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TRIPS post-2005 and access to new antiretroviral treatments in southern countries: issues and challenges.
    Orsi F; D'Almeida C; Hasenclever L; Camara M; Tigre P; Coriat B
    AIDS; 2007 Oct; 21(15):1997-2003. PubMed ID: 17885289
    [No Abstract]   [Full Text] [Related]  

  • 3. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S; Antunes OA; Fortunak JM
    Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intellectual property rights, market competition and access to affordable antiretrovirals.
    Pascual F
    Antivir Ther; 2014; 19 Suppl 3():57-67. PubMed ID: 25309984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A one-time-only combination: Emergency medicine exports and the TRIPS agreement under Canada's access to medicines regime.
    Weber A; Mills L
    Health Hum Rights; 2010 Jun; 12(1):109-22. PubMed ID: 20930258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug resistance, patent resistance: Indian pharmaceuticals and the impact of a new patent regime.
    Halliburton M
    Glob Public Health; 2009; 4(6):515-27. PubMed ID: 19548158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Examining the production costs of antiretroviral drugs.
    Pinheiro E; Vasan A; Kim JY; Lee E; Guimier JM; Perriens J
    AIDS; 2006 Aug; 20(13):1745-52. PubMed ID: 16931939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
    Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
    Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The economics of effective AIDS treatment in Thailand.
    Over M; Revenga A; Masaki E; Peerapatanapokin W; Gold J; Tangcharoensathien V; Thanprasertsuk S
    AIDS; 2007 Jul; 21 Suppl 4():S105-16. PubMed ID: 17620745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of intellectual property rights in treatment access: challenges and solutions.
    't Hoen E; Passarelli CA
    Curr Opin HIV AIDS; 2013 Jan; 8(1):70-4. PubMed ID: 23201855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Companies reduce prices for HIV drugs in developing countries.
    Gottlieb S
    Bull World Health Organ; 2000; 78(6):862. PubMed ID: 10916926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries.
    Waning B; Diedrichsen E; Moon S
    J Int AIDS Soc; 2010 Sep; 13():35. PubMed ID: 20840741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The economics of health care in developing countries: what the fight against the AIDS epidemics has changed].
    Moatti JP
    C R Biol; 2008 Dec; 331(12):964-72. PubMed ID: 19027697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GATT and the gap: how to save lives.
    James JS
    AIDS Treat News; 1998 Nov; (No 307):1, 3-6. PubMed ID: 11366123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs associated with combination antiretroviral therapy in HIV-infected patients.
    Yazdanpanah Y
    J Antimicrob Chemother; 2004 Apr; 53(4):558-61. PubMed ID: 14985277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens.
    Renaud-Théry F; Nguimfack BD; Vitoria M; Lee E; Graaff P; Samb B; Perriëns J
    AIDS; 2007 Jul; 21 Suppl 4():S89-95. PubMed ID: 17620758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustaining treatment costs: who will pay?
    Zewdie D; De Cock K; Piot P
    AIDS; 2007 Jul; 21 Suppl 4():S1-4. PubMed ID: 17620744
    [No Abstract]   [Full Text] [Related]  

  • 18. Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment.
    Nunn AS; Fonseca EM; Bastos FI; Gruskin S; Salomon JA
    PLoS Med; 2007 Nov; 4(11):e305. PubMed ID: 18001145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. World Trade Organization still threatens supply of affordable AIDS drugs.
    Hagmann M
    Bull World Health Organ; 2002; 80(9):762-3. PubMed ID: 12378300
    [No Abstract]   [Full Text] [Related]  

  • 20. Addressing legal and political barriers to global pharmaceutical access: options for remedying the impact of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and the imposition of TRIPS-plus standards.
    Cohen-Kohler JC; Forman L; Lipkus N
    Health Econ Policy Law; 2008 Jul; 3(Pt 3):229-56. PubMed ID: 18634618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.